{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Pre-treatment deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"2"}]}],"title":"On-treatment deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"191"},{"groupId":"OG002","value":"9"}]}],"title":"Post-treatment deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"238"},{"groupId":"OG002","value":"11"}]}],"title":"All deaths"}],"denoms":[{"counts":[{"groupId":"OG000","value":"351"},{"groupId":"OG001","value":"349"},{"groupId":"OG002","value":"34"}],"units":"Participants"}],"description":"Pre-treatment deaths were collected from screening visit up to the first day of treatment, for a maximum duration of 28 days. Patients who died during the screening period are considered as screen failure.\n\nOn treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 81.1 months (treatment duration ranged from 0.1 to 80.1 months).\n\nDeaths post treatment survival follow up were collected after the on- treatment period, up to approximately 6 years. Patients who didn't die during the on-treatment period and had not stopped study participation at the time of data cut-off (end of study) were censored.","groups":[{"description":"Dabrafenib 150 milligrams (mg) orally twice daily (BID) and Trametinib 2 mg orally once daily until disease progression, death, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Dabrafenib Plus Trametinib"},{"description":"Vemurafenib 960 mg orally BID until disease progression, death, unacceptable toxicity, or withdrawal of consent.","id":"OG001","title":"Vemurafenib"},{"description":"With Protocol Amendment 7, patients still receiving study treatment on the Vemurafenib monotherapy arm were allowed to cross over to the Dabrafenib and Trametinib combination arm.","id":"OG002","title":"Crossover Dabrafenib + Trametinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Clinical database population; all treated patients and patients who died during screening.","reportingStatus":"POSTED","timeFrame":"up to 28 days before Day 1 (Screening), up to 81.1 months (on-treatment), up to approximately 6 years (study duration)","title":"All Collected Deaths","type":"POST_HOC","unitOfMeasure":"Participants"}